Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Immunol. 2022 Nov 24;13:1060497. doi: 10.3389/fimmu.2022.1060497. eCollection 2022.
Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.
胃癌（GC）是全球癌症发病率和死亡率的主要原因之一。作为主要的突破方向，免疫检查点抑制剂的应用使 GC 患者有更好的预后，其中免疫疗法中的 PD-L1/PD-1 抑制剂具有良好的抗肿瘤免疫疗效。进一步了解 PD-L1 在 GC 中的调控机制可能会给免疫治疗带来实质性的进展。在这篇综述中，我们提供了关于 PD-L1 的内源性和外源性调控机制及其生物学功能的信息，并结合了目前 GC 中 PD-L1/PD-1 抑制剂的临床试验。报道了 PD-L1 引起的恶性生物学表型及其相应的临床联合治疗方案。确定免疫治疗潜在疗效的生物标志物，并结合患者的分子特征指定临床免疫治疗方案，可能最大限度地提高临床获益和更好的预后。
